

Aurora kinase inhibitor nanoparticles target tumors *in vivo*

Science Translational Medicine

8, 325ra17

DOI: [10.1126/scitranslmed.aad2355](https://doi.org/10.1126/scitranslmed.aad2355)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Nanoparticles improve profile of molecularly targeted cancer drug. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 231-231.	21.5	27
3	Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 751-755.	2.4	2
4	Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. <i>Journal of Hematology and Oncology</i> , 2016, 9, 105.	6.9	302
5	Nanomedicines: From Bench to Bedside and Beyond. <i>AAPS Journal</i> , 2016, 18, 1373-1378.	2.2	119
6	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines <i>in Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2314-2322.	1.9	81
7	A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products. <i>AAPS Journal</i> , 2016, 18, 1354-1365.	2.2	42
8	Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 843-857.	4.0	18
9	Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca. <i>Drug Discovery Today</i> , 2016, 21, 1596-1608.	3.2	14
10	Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. <i>Pharmaceutical Research</i> , 2016, 33, 2373-2387.	1.7	1,976
11	A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system. <i>Journal of Controlled Release</i> , 2016, 229, 106-119.	4.8	59
12	Are Accurins the cure for Aurora kinase inhibitors?. <i>Science Translational Medicine</i> , 2016, 8, 325fs4.	5.8	3
13	Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. <i>Advanced Drug Delivery Reviews</i> , 2017, 113, 61-86.	6.6	60
14	Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. <i>Advanced Drug Delivery Reviews</i> , 2017, 108, 25-38.	6.6	881
15	Clinical and commercial translation of advanced polymeric nanoparticle systems: opportunities and material challenges. <i>Translational Materials Research</i> , 2017, 4, 014001.	1.2	23
16	Comprehensive study of the drug delivery properties of poly(L-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. <i>Journal of Controlled Release</i> , 2017, 261, 31-42.	4.8	53
17	Nanomaterial-Enabled Cancer Therapy. <i>Molecular Therapy</i> , 2017, 25, 1501-1513.	3.7	110
18	Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1031-1040.	1.9	25
19	Ambient Mass Spectrometry in Cancer Research. <i>Advances in Cancer Research</i> , 2017, 134, 231-256.	1.9	61

#	ARTICLE	IF	CITATIONS
20	Synthesis and Evaluation of Thiazoloquinolinones with Linkers To Enable Targeting of CD38. ACS Medicinal Chemistry Letters, 2017, 8, 196-200.	1.3	1
21	Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. Journal of Controlled Release, 2017, 247, 73-85.	4.8	32
22	Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. Molecular Pharmaceutics, 2017, 14, 4551-4559.	2.3	30
23	Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation. ACS Nano, 2017, 11, 10797-10807.	7.3	71
24	Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. Journal of Controlled Release, 2017, 268, 92-101.	4.8	24
25	The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 881-894.	1.1	61
26	Mass Spectrometry Imaging in Oncology Drug Discovery. Advances in Cancer Research, 2017, 134, 133-171.	1.9	37
27	T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nature Communications, 2017, 8, 1747.	5.8	336
28	Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma. EBioMedicine, 2017, 26, 100-111.	2.7	34
29	Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies. Nanomedicine, 2017, 12, 1873-1889.	1.7	53
30	Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 2017, 17, 20-37.	12.8	4,153
31	Aurora kinases: novel therapy targets in cancers. Oncotarget, 2017, 8, 23937-23954.	0.8	260
32	Quantitation of Endogenous Metabolites in Mouse Tumors Using Mass-Spectrometry Imaging. Analytical Chemistry, 2018, 90, 6051-6058.	3.2	56
33	Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1301-1313.	1.7	21
34	Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small. Journal of Controlled Release, 2018, 272, 159-168.	4.8	55
35	Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Advances in Cancer Research, 2018, 137, 115-170.	1.9	183
36	Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano, 2018, 12, 24-43.	7.3	192
37	Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. Molecular Cancer Therapeutics, 2018, 17, 3-16.	1.9	81

#	ARTICLE	IF	CITATIONS
38	Recent advances in nanomedicine for sepsis treatment. <i>Therapeutic Delivery</i> , 2018, 9, 435-450.	1.2	23
39	Nano-Photothermal ablation effect of Hydrophilic and Hydrophobic Functionalized Gold Nanorods on <i>Staphylococcus aureus</i> and <i>Propionibacterium acnes</i> . <i>Scientific Reports</i> , 2018, 8, 6881.	1.6	48
40	Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy. <i>Drug Discovery Today: Technologies</i> , 2018, 30, 63-69.	4.0	61
41	Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 9449-9470.	1.7	54
42	Topical Lyophilized Targeted Lipid Nanoparticles in the Restoration of Skin Barrier Function following Burn Wound. <i>Molecular Therapy</i> , 2018, 26, 2178-2188.	3.7	44
43	Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors. <i>Scientific Reports</i> , 2018, 8, 11417.	1.6	60
44	Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications. <i>Progress in Polymer Science</i> , 2018, 87, 107-164.	11.8	177
45	Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3093-3099.	1.0	64
46	Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo. <i>Journal of Controlled Release</i> , 2018, 287, 121-131.	4.8	96
47	Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells. <i>Molecular Pharmaceutics</i> , 2018, 15, 3046-3059.	2.3	11
48	Advances in treatment formulations for acute myeloid leukemia. <i>Drug Discovery Today</i> , 2018, 23, 1936-1949.	3.2	40
49	Focus on Fundamentals: Achieving Effective Nanoparticle Targeting. <i>Trends in Molecular Medicine</i> , 2018, 24, 598-606.	3.5	77
50	Using Large Datasets to Understand Nanotechnology. <i>Advanced Materials</i> , 2019, 31, e1902798.	11.1	45
51	Role of self-assembly conditions and amphiphilic balance on nanoparticle formation of PEG- ϵ -PDLLA copolymers in aqueous environments. <i>Journal of Polymer Science Part A</i> , 2019, 57, 1801-1810.	2.5	20
52	Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells. <i>Cell Cycle</i> , 2019, 18, 2281-2292.	1.3	5
53	Development of a Physiologically-Based Mathematical Model for Quantifying Nanoparticle Distribution in Tumors. , 2019, 2019, 2852-2855.		1
54	Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β -Cyclodextrin-PEG Copolymer Based Delivery Platform. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9541-9559.	2.9	7
55	Smart cancer nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 1007-1017.	15.6	776

#	ARTICLE	IF	CITATIONS
56	Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine. <i>Bioconjugate Chemistry</i> , 2019, 30, 2300-2311.	1.8	161
57	Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease. <i>Journal of Controlled Release</i> , 2019, 311-312, 257-272.	4.8	22
58	Bioanalysis of Targeted Nanoparticles in Monkey Plasma via LC-MS/MS. <i>Analytical Chemistry</i> , 2019, 91, 13874-13882.	3.2	8
59	Polymeric Nanomaterials. , 2019, , 1-66.		25
60	Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer. <i>Clinica Chimica Acta</i> , 2019, 492, 12-19.	0.5	31
61	TRAIL encapsulated to polypeptide-crosslinked nanogel exhibits increased anti-inflammatory activities in <i>Klebsiella pneumoniae</i> -induced sepsis treatment. <i>Materials Science and Engineering C</i> , 2019, 102, 85-95.	3.8	27
62	Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. <i>Molecular Pharmaceutics</i> , 2019, 16, 1958-1970.	2.3	72
63	Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 909-919.	1.9	13
64	High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 4552-4566.	3.2	30
65	Penetration and Uptake of Nanoparticles in 3D Tumor Spheroids. <i>Bioconjugate Chemistry</i> , 2019, 30, 1371-1384.	1.8	141
66	Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3052-3061.	3.3	32
67	Application of nanoparticle-based siRNA and CRISPR/Cas9 delivery systems in gene-targeted therapy. <i>Nanomedicine</i> , 2019, 14, 511-514.	1.7	14
68	Recalcitrant Issues and New Frontiers in Nano-Pharmacology. <i>Frontiers in Pharmacology</i> , 2019, 10, 1369.	1.6	28
69	Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers. <i>Nanoscale Advances</i> , 2019, 1, 4207-4237.	2.2	135
70	Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. <i>Journal of Controlled Release</i> , 2019, 294, 102-113.	4.8	175
71	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. <i>European Respiratory Journal</i> , 2019, 53, 1801562.	3.1	61
72	Hybrid Nanostructures in Targeted Drug Delivery. , 2019, , 139-158.		11
73	Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1590-1597.	1.6	3

#	ARTICLE	IF	CITATIONS
74	Cells Lacking the <i>p53</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. <i>Cancer Discovery</i> , 2019, 9, 230-247.	7.7	119
75	Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. <i>Cancer Letters</i> , 2019, 440-441, 64-81.	3.2	60
76	Controlling the Surface Properties of Binary Polymer Brush-Coated Colloids via Targeted Nanoparticles. <i>Journal of Physical Chemistry B</i> , 2019, 123, 258-265.	1.2	2
77	Mass spectrometry imaging and its application in pharmaceutical research and development: A concise review. <i>International Journal of Mass Spectrometry</i> , 2019, 437, 99-112.	0.7	111
78	Critical considerations for targeting colorectal liver metastases with nanotechnology. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1588.	3.3	14
79	High-resolution 3D visualization of nanomedicine distribution in tumors. <i>Theranostics</i> , 2020, 10, 880-897.	4.6	13
80	Mitotic Poisons in Research and Medicine. <i>Molecules</i> , 2020, 25, 4632.	1.7	25
81	Therapeutic potential of polypeptide-based conjugates: Rational design and analytical tools that can boost clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 136-169.	6.6	42
82	Drug delivery—the increasing momentum. <i>Drug Delivery and Translational Research</i> , 2020, 10, 1888-1894.	3.0	4
83	Brave new world revisited: Focus on nanomedicine. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 36-49.	1.0	18
84	Nanoencapsulation of triterpene 3 β ,6 α ,16 α -trihydroxylup-20(29)-ene from <i>Combretum leprosum</i> as strategy to improve its cytotoxicity against cancer cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127469.	1.0	3
85	Nanopharmaceuticals: A focus on their clinical translatability. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119098.	2.6	44
86	Residual Solvents in Nanomedicine and Lipid-Based Drug Delivery Systems: a Case Study to Better Understand Processes. <i>Pharmaceutical Research</i> , 2020, 37, 149.	1.7	19
87	A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery. <i>SLAS Discovery</i> , 2020, 25, 963-976.	1.4	42
88	Engineering Prodrug Nanomedicine for Cancer Immunotherapy. <i>Advanced Science</i> , 2020, 7, 2002365.	5.6	71
89	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	101
90	Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2020, 10, 15535.	1.6	9
91	Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6018.	1.8	52

#	ARTICLE	IF	CITATIONS
92	Development of a Highly Specific Anti-drug Antibody Assay in Support of a Nanoparticle-based Therapeutic. <i>AAPS Journal</i> , 2020, 22, 81.	2.2	0
93	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. <i>ACS Nano</i> , 2020, 14, 7760-7782.	7.3	289
94	A smart approach to enable preclinical studies in pharmaceutical industry: PLGA-based extended release formulation platform for subcutaneous applications. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 635-645.	0.9	2
95	The solid progress of nanomedicine. <i>Drug Delivery and Translational Research</i> , 2020, 10, 726-729.	3.0	91
96	Nanocarriers as Magic Bullets in the Treatment of Leukemia. <i>Nanomaterials</i> , 2020, 10, 276.	1.9	38
97	Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment. <i>Theranostics</i> , 2020, 10, 1884-1909.	4.6	30
98	Evaluation of Particle Size Techniques to Support the Development of Manufacturing Scale Nanoparticles for Application in Pharmaceuticals. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2284-2293.	1.6	10
99	Internal liquid crystal structures in nanocarriers containing drug hydrophobic ion pairs dictate drug release. <i>Journal of Colloid and Interface Science</i> , 2021, 582, 815-824.	5.0	13
100	Clinical Translation of Self-Assembled Cancer Nanomedicines. <i>Advanced Therapeutics</i> , 2021, 4, .	1.6	34
101	Behavioral, Histopathologic, and Molecular Biological Responses of Nanoparticle- and Solution-Based Formulations of Vincristine in Mice. <i>International Journal of Toxicology</i> , 2021, 40, 40-51.	0.6	3
102	Nanomedicine in treatment of breast cancer – A challenge to conventional therapy. <i>Seminars in Cancer Biology</i> , 2021, 69, 279-292.	4.3	59
103	Application of Nanotechnology in the COVID-19 Pandemic. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 623-649.	3.3	60
104	Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. <i>Communications Biology</i> , 2021, 4, 112.	2.0	63
105	Nanomaterials in Medicine. <i>Springer Series in Biomaterials Science and Engineering</i> , 2021, , 197-210.	0.7	0
106	Method to Investigate the Distribution of Water-Soluble Drug-Delivery Systems in Fresh Frozen Tissues Using Imaging Mass Cytometry. <i>Analytical Chemistry</i> , 2021, 93, 3742-3749.	3.2	3
107	Targeted drug delivery strategies for precision medicines. <i>Nature Reviews Materials</i> , 2021, 6, 351-370.	23.3	388
108	MALDI-MSI analysis of cancer drugs: Significance, advances, and applications. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 136, 116183.	5.8	18
109	Preparation and Release Profiles in Vitro/Vivo of Galantamine Pamoate Loaded Poly (Lactide-co-Glycolide) (PLGA) Microspheres. <i>Frontiers in Pharmacology</i> , 2020, 11, 619327.	1.6	3

#	ARTICLE	IF	CITATIONS
110	Highway to Successâ€”Developing Advanced Polymer Therapeutics. <i>Advanced Therapeutics</i> , 2021, 4, 2000285.	1.6	16
111	Targeting pan-essential genes in cancer: Challenges and opportunities. <i>Cancer Cell</i> , 2021, 39, 466-479.	7.7	88
112	Applications of Nanosized-Lipid-Based Drug Delivery Systems in Wound Care. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4915.	1.3	48
113	Highly-loaded protein nanocarriers prepared by Flash NanoPrecipitation with hydrophobic ion pairing. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120397.	2.6	7
114	Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120477.	2.6	26
115	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 551-569.	21.5	497
116	The Multifunctionally Graded System for a Controlled Size Effect on Iron Oxideâ€”Gold Based Core-Shell Nanoparticles. <i>Nanomaterials</i> , 2021, 11, 1695.	1.9	5
117	Current hurdles to the translation of nanomedicines from bench to the clinic. <i>Drug Delivery and Translational Research</i> , 2022, 12, 500-525.	3.0	92
118	Measuring the Rate of In-vitro Drug Release From Polymeric Nanoparticles by ¹⁹ F Solution State NMR Spectroscopy. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 3546-3549.	1.6	3
119	Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112482.	2.6	14
120	Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. <i>Science Advances</i> , 2020, 6, eaaz8521.	4.7	22
121	Safety, pharmacokinetic, and antitumor activity of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13586-e13586.	0.8	4
122	Nanoengineering in biomedicine: Current development and future perspectives. <i>Nanotechnology Reviews</i> , 2020, 9, 700-715.	2.6	42
123	On Cancer Electro- and Nano-Chemotherapy. <i>Journal of Cancer Prevention & Current Research</i> , 2017, 7, .	0.1	1
124	Nanoparticles for hematologic diseases detection and treatment. <i>Hematology & Medical Oncology</i> , 2019, 4, 1000183.	0.1	5
125	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <i>Oncotarget</i> , 2018, 9, 18540-18547.	0.8	15
126	Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. <i>Annals of Translational Medicine</i> , 2019, 7, 452-452.	0.7	9
127	Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 7234-7255.	1.2	7

#	ARTICLE	IF	CITATIONS
128	Desorption electrospray ionization mass spectrometry imaging in discovery and development of novel therapies. <i>Mass Spectrometry Reviews</i> , 2023, 42, 751-778.	2.8	22
129	Challenges in Development of Nanomedicine for Treatment of Cancer. <i>Journal of Cancer Research Updates</i> , 0, 8, 64-69.	0.3	0
130	The application of nanotechnology in cancer immunotherapy. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2020, 74, 131-143.	0.1	0
131	Nanopharmacology Intervention in Human Pathological Diseases. , 2020, , 123-139.		0
132	Polymer-Based Tumor-targeted Nanosystems. , 2020, , 371-411.		0
133	Recent Advances of Ambient Mass Spectrometry Imaging and Its Applications in Lipid and Metabolite Analysis. <i>Metabolites</i> , 2021, 11, 780.	1.3	19
134	The Hitchhiker's™ Guide to Human Therapeutic Nanoparticle Development. <i>Pharmaceutics</i> , 2022, 14, 247.	2.0	14
135	Towards principled design of cancer nanomedicine to accelerate clinical translation. <i>Materials Today Bio</i> , 2022, 13, 100208.	2.6	47
136	Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution. <i>Theranostics</i> , 2022, 12, 2162-2174.	4.6	9
137	Delivery strategies in treatments of leukemia. <i>Chemical Society Reviews</i> , 2022, 51, 2121-2144.	18.7	17
138	CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes. <i>Cancers</i> , 2022, 14, 1345.	1.7	7
139	Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. <i>Molecular Pharmaceutics</i> , 2022, 19, 172-187.	2.3	0
140	Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. <i>Pharmaceutics</i> , 2022, 14, 866.	2.0	17
141	Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis on Drug Targeting to Cancer Cells Through Nanoparticles. <i>Letters in Drug Design and Discovery</i> , 2022, 19, .	0.4	0
142	Sustained endosomal release of a neurokinin-1 receptor antagonist from nanostars provides long-lasting relief of chronic pain. <i>Biomaterials</i> , 2022, 285, 121536.	5.7	16
143	Kinase inhibitors: An overview. , 2022, , 1-22.		2
144	Glycogen kinase 3 inhibitor nanoformulation as an alternative strategy to inhibit PD-1 immune checkpoint. <i>International Journal of Pharmaceutics</i> , 2022, 622, 121845.	2.6	5
145	Therapeutic significance of nano- and biosensor technology in combating SARS-CoV-2: a review. <i>Applied Nanoscience (Switzerland)</i> , 2022, 12, 3127-3140.	1.6	3

#	ARTICLE	IF	CITATIONS
146	Magnetic Nanoparticles for Imaging, Diagnosis, and Drug-Delivery Applications. , 2022, , 98-129.		0
147	Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma. Journal of Controlled Release, 2022, 348, 420-430.	4.8	4
148	A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects. Recent Patents on Nanotechnology, 2022, 16, .	0.7	0
149	Biogenic polymer-encapsulated diosgenin nanoparticles: Biodistribution, pharmacokinetics, cellular internalization, and anticancer potential in breast cancer cells and tumor xenograft. Journal of Drug Delivery Science and Technology, 2022, 76, 103743.	1.4	3
150	An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors. Frontiers in Oncology, 0, 12, .	1.3	12
152	Volumetric imaging of optically cleared and fluorescently labeled animal tissue (VIOLA) for quantifying the 3D biodistribution of nanoparticles at cellular resolution in tumor tissue. Journal of Controlled Release, 2023, 354, 244-259.	4.8	1
153	Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nature Reviews Materials, 2023, 8, 282-300.	23.3	88
154	Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. Pharmaceutics, 2023, 15, 451.	2.0	6
155	Utilization of kinase inhibitors as novel therapeutic drug targets: A review. Oncology Research, 2022, 30, 221-230.	0.6	4
156	Delivering on the promise of protein degraders. Nature Reviews Drug Discovery, 2023, 22, 410-427.	21.5	16
157	Dual-Labelled Nanoparticles Inform on the Stability of Fluorescent Labels In Vivo. Pharmaceutics, 2023, 15, 769.	2.0	2
158	Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours. British Journal of Cancer, 2023, 128, 1906-1915.	2.9	6
159	Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis. BMC Cancer, 2023, 23, .	1.1	3
160	Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects. Journal of Nanobiotechnology, 2023, 21, .	4.2	0